Literature DB >> 19087209

Validation of the current prognostic models for nonmetastatic renal cell carcinoma after nephrectomy in Chinese population: a 15-year single center experience.

Zheng Liu1, Jiaju Lv, Kejia Ding, Qiang Fu, Qingwei Cao, Facheng Wang.   

Abstract

OBJECTIVES: To explore the applicability of the current prognostic models for nonmetastatic renal cell carcinoma in the Chinese population based on a single center experience.
METHODS: Clinical and pathological variables of 653 nonmetastatic renal cell carcinoma patients were retrospectively reviewed. Seven models were used to predict the prognosis, including the Yaycioglu model, the Cindolo model, the University of California Los Angeles Integrated Staging System model, the stage, size, grade, and necrosis model, the Kattan nomogram, the Sorbellini nomogram and the Karakiewicz nomogram. Three different end-points were used for validation, including overall survival, cancer-specific survival, and recurrence-free survival. Survival was estimated using the Kaplan-Meier method. Discriminating ability was assessed using the Harrell's concordance-index.
RESULTS: At the last follow up, 159 patients had died due to various causes, and disease recurrence occurred in 156 patients. The discriminating ability of all models was confirmed in the Chinese population. Nomograms discriminate better than algorithms, regardless of end-points. The Kattan nomogram was the most accurate, with the highest concordance-indexes of 0.752, 0.793 and 0.841 for overall survival, cancer-specific survival, and recurrence-free survival, respectively.
CONCLUSIONS: The current prognostic models were developed and validated entirely based on Caucasian populations. This study defines the general applicability of the models for Chinese patients with nonmetastatic renal cell carcinoma treated with nephrectomy. The Kattan model was found to be the most accurate. The Cindolo model performed well in some situations, although only including clinical presentation and size of tumor. Therefore, models should be chosen according to different environments and purposes.

Entities:  

Mesh:

Year:  2008        PMID: 19087209     DOI: 10.1111/j.1442-2042.2008.02229.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  6 in total

1.  Decision curve analysis and external validation of the postoperative Karakiewicz nomogram for renal cell carcinoma based on a large single-center study cohort.

Authors:  Stefan Zastrow; Sabine Brookman-May; Thi Anh Phuong Cong; Stanislaw Jurk; Immanuel von Bar; Vladimir Novotny; Manfred Wirth
Journal:  World J Urol       Date:  2014-05-22       Impact factor: 4.226

2.  Urinary collecting system invasion is no independent prognostic factor in renal cell carcinoma.

Authors:  Sandra Waalkes; Axel S Merseburger; Thomas R W Herrmann; Mario W Kramer; Gerd Wegener; Julia Rustemeier; Rainer Hofmann; Markus A Kuczyk; Andres J Schrader
Journal:  World J Urol       Date:  2010-03-18       Impact factor: 4.226

Review 3.  Predictive models for the practical management of renal cell carcinoma.

Authors:  Lui Shiong Lee; Min-Han Tan
Journal:  Nat Rev Urol       Date:  2012-01-10       Impact factor: 14.432

4.  Accuracy capabilities comparisons between Karakiewicz, Kattan and Cindolo nomograms in predicting outcomes for renal cancer carcinoma: A systematic review and meta-analysis.

Authors:  Giorgio Ivan Russo; Alessandro Di Rosa; Vincenzo Favilla; Eugenia Fragalà; Tommaso Castelli; Salvatore Privitera; Sebastiano Cimino; Giuseppe Morgia
Journal:  Can Urol Assoc J       Date:  2015 May-Jun       Impact factor: 1.862

5.  Prognostic analysis of postoperative clinically nonmetastatic renal cell carcinoma.

Authors:  Yanxiang Shao; Sanchao Xiong; Guangxi Sun; Weichao Dou; Xu Hu; Weixiao Yang; Thongher Lia; Shi Deng; Qiang Wei; Hao Zeng; Xiang Li
Journal:  Cancer Med       Date:  2019-12-16       Impact factor: 4.452

6.  Prognostic factors of overall survival in renal cancer patients - single oncological center study.

Authors:  Tomasz Drewniak; Marek Sandheim; Jacek Jakubowski; Kajetan Juszczak; Andrzej Wojciech Stelmach
Journal:  Cent European J Urol       Date:  2013-11-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.